Insider · CIK 0001639481
Annalisa Jenkins
Files at SKYE (Skye Bioscience, Inc.), MREO (Mereo BioPharma Group plc), CMPS (COMPASS Pathways plc). First filing -, latest -.
In brief
Annalisa Jenkins files SEC Form 4 as director at SKYE (Skye Bioscience, Inc.), and also at MREO (Mereo BioPharma Group plc), CMPS (COMPASS Pathways plc). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Annalisa Jenkins has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 10, 2026 | CMPS COMPASS Pathways plc | 26,000 0.02% of outstanding | $346k | Aug 10, 2026 | $1.1M |
| Aug 7, 2026 | CMPS COMPASS Pathways plc | 83,771 0.06% of outstanding | $1.1M | Aug 7, 2026 | none |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Apr 2, 2026 |
| Feb 26, 2026 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +66,000 | $0.00 | $0 | 66,000 | Feb 27, 2026 |
| Feb 26, 2026 | MREO Mereo BioPharma Group plc | AGrant or award Deferred Restricted Stock Unitsderivative | +106,848 | - | - | 106,848 | Feb 27, 2026 |
| Feb 6, 2026 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Feb 9, 2026 |
| Jun 12, 2025 | CMPS COMPASS Pathways plc | AGrant or award Share Option (Right to Buy)derivative | +26,000 | $0.00 | $0 | 26,000 | Jun 13, 2025 |
| Feb 24, 2025 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Feb 26, 2025 |
| Feb 5, 2025 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Feb 6, 2025 |
| Feb 5, 2025 | MREO Mereo BioPharma Group plc | AGrant or award Deferred Restricted Stock Unitsderivative | +15,243 | - | - | 15,243 | Feb 6, 2025 |
| Oct 28, 2024 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Oct 30, 2024 |
| May 9, 2024 | CMPS COMPASS Pathways plc | AGrant or award Share Option (Right to Buy)derivative | +26,000 | $0.00 | $0 | 26,000 | May 13, 2024 |
| May 1, 2024 | CMPS COMPASS Pathways plc | FTax withholding Ordinary Shares | -211 | $8.48 | $1,789 | 19,641 | May 3, 2024 |
| Feb 29, 2024 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Mar 4, 2024 |
| Feb 8, 2024 | MREO Mereo BioPharma Group plc | AGrant or award Share Options (Right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Feb 9, 2024 |
| Feb 8, 2024 | MREO Mereo BioPharma Group plc | AGrant or award Deferred Restricted Stock Unitsderivative | +14,947 | - | - | 14,947 | Feb 9, 2024 |
| Feb 1, 2024 | CMPS COMPASS Pathways plc | FTax withholding Ordinary Shares | -175 | $11.34 | $1,985 | 19,852 | Feb 5, 2024 |
| Nov 1, 2023 | CMPS COMPASS Pathways plc | FTax withholding Ordinary Shares | -143 | $5.78 | $827 | 20,027 | Nov 2, 2023 |
Questions about Annalisa Jenkins
Answered from the filings on this page, as of the latest one.
Is Annalisa Jenkins buying or selling?
Annalisa Jenkins has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Annalisa Jenkins's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Annalisa Jenkins has 0.
Where does Annalisa Jenkins file Form 4?
Annalisa Jenkins has filed Form 4 at SKYE (Skye Bioscience, Inc.); MREO (Mereo BioPharma Group plc); CMPS (COMPASS Pathways plc). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.